In many Southeast Asian countries, chewing these
leaves is a common occurrence, and not considered addictive. Reportedly,
chewing kratom leaves makes someone more alert, talkative, and sociable. You
could compare this habitual use to that of people in the Andean region commonly
chewing coca leaves, or many of us who drink coffee on a regular basis.
Kratom contains natural alkaloids (mitragynine, 7-hydroxymitragynine, and
MGM-9) that act as agonists of both opioid and alpha-2 receptors. As we
have discussed in class, alpha-2 receptors are adrenergic receptors mainly
located in the membrane of adrenergic axon terminals and in the pancreas. The
effect of binding inhibits norepinephrine release from axon terminals – for
example, inhibiting insulin secretion in the pancreas. Alpha-2 agonists are
used in the treatment of hypertension; ADHD; symptoms of alcohol or opioid
withdrawal; and adjuncts for sedation (Ismail et al, 2019; Boron &
Boulpaep, 2017; Giovannitti,
Thoms, & Crawford, 2015).
There is inadequate
research regarding the effectiveness of Kratom for these medicinal uses. It
seems that its’ pharmacologic properties may have some promise as an opioid alternative,
although some studies have shown that kratom can lead to similar withdrawal symptoms.
Side effects of kratom include hypotension, respiratory depression,
hallucinations, aggression, and vomiting. There have been several reported
cases of acute liver injury from chronic kratom use, as well as instances of
seizures, coma, and death from overdose. The US FDA has illuded to concern
about its’ adverse effects, potential drug interactions, and addictive
properties. But at this time, kratom is legal and minimally regulated in the
vast majority of the US and can be bought easily online. (LiverTox,
2012 ; Mayo Clinic, 2020)
Ethically, is it
permissible to allow for the legal sell and purchase of kratom when we are
aware of potentially fatal consequences? On the basis of autonomy, should individuals
addicted to opioids to have the option to explore this ‘natural’ alternative?
In respect to non-malfeasance, should the FDA work harder to put kratom behind
the counter? The last thought I will leave you with is that kratom does not
show up on standard drug tests – would you be comfortable with your surgeon
taking kratom? Is it equitable for someone to lose their job for medical
marijuana use, but a coworker who uses kratom chronically to keep theirs?
References:
Boron, W. F., & Boulpaep, E. L. (2017). Medical
physiology. Philadelphia, PA: Elsevier.
Cracking Down on Kratom: FDA Investigation, Enforcement,
Seizure, and Recall of Products Reported to Contain Kratom. (2018, November
30). Retrieved November 17, 2020, from
https://www.fdli.org/2018/08/update-cracking-down-on-kratom-fda-investigation-enforcement-seizure-and-recall-of-products-reported-to-contain-kratom/
Giovannitti, J.
A., Jr, Thoms, S. M., & Crawford, J. J. (2015). Alpha-2 adrenergic receptor
agonists: a review of current clinical applications. Anesthesia
progress, 62(1), 31–39. https://doi.org/10.2344/0003-3006-62.1.31
Ismail I, Wahab
S, Sidi H, Das S, Lin LJ, Razali R. Kratom and Future Treatment for the Opioid
Addiction and Chronic Pain: Periculo Beneficium? Curr Drug Targets.
2019;20(2):166-172. doi: 10.2174/1389450118666170425154120. PMID: 28443503
LiverTox: Clinical and Research Information on Drug-Induced
Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and
Digestive and Kidney Diseases; 2012-. Kratom. [Updated 2020 Apr
3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548231/
Mayo Clinic. Kratom: Unsafe and ineffective. (2020, June
03). Retrieved November 17, 2020, from
https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/kratom/art-20402171
Coming from a purely anecdotal standpoint, I believe Kratom should be entirely legal and open for use, especially in the treatment of pain. I take this position because I have family friends that have been able to entirely ween-off of very heavy opioids prescribed for chronic pain using kratom. While you did mention that some overdoses have occurred, I would be interested in a toxicity comparison between kratom and other forms of opioids commonly prescribed for pain. I appreciate the fact that you brought up how kratom cannot be tested for, I think this is an important point. But it is relevant to remember that surgeons aren't taking breathalyzers before operating either...
ReplyDeleteI think more good would come from either keeping kratom entirely legal to buy by persons 18 or older, or better, by way of a prescription in order to treat pain, get off of pain meds, reduce anxiety, etc. than would come from making it illegal.
Last thought: how does the body-wide damage created by common analgesics such as ibuprofen in the long term compare to equivalent doses of kratom?
Thanks for your reply, Neil! I am glad to hear that kratom can be very beneficial. I was intrigued by your comment regarding toxicity of kratom vs. opioids and came across an analytical study of kratom exposures reported to poison control centers in the US from 2011-2017. Researchers noted that Kratom is a difficult toxin to manage due to doses not being well defined as it is a plant product, and the toxicity can present in many different ways and time frames depending on the individual, what else they have been taking, and if they have any tolerance to opioids.
DeleteWhile kratom overdose typically encompasses the respiratory depression and unconsciousness that is seen in opioid overdose, it has also been accompanied by things like seizure, agitation, tachycardia, and hypertension. Those symptoms were associated with norepinephrine and serotonin reuptake inhibition rather than the opioid receptor itself. With more variables, it seems more complex to manage. However, the opioid crisis is far more prevalent than kratom abuse at this point.
I appreciate your other points – it seems there is much more research to be done!
Reference:
Sara Post, Henry A. Spiller, Thitphalak Chounthirath & Gary A. Smith (2019) Kratom exposures reported to United States poison control centers: 2011–2017, Clinical Toxicology, 57:10, 847-854, DOI: 10.1080/15563650.2019.1569236